Suppr超能文献

血管收缩剂和白蛋白输注在1型肝肾综合征中的当前应用情况

Current position of vasoconstrictor and albumin infusion for type 1 hepatorenal syndrome.

作者信息

Sobhonslidsuk Abhasnee

机构信息

Abhasnee Sobhonslidsuk, Division of Gastroenterology and Hepatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand.

出版信息

World J Gastrointest Pharmacol Ther. 2015 Aug 6;6(3):28-31. doi: 10.4292/wjgpt.v6.i3.28.

Abstract

Spontaneous bacterial peritonitis (SBP), refractory ascites, hepatorenal syndrome (HRS), hyponatremia and hepatic encephalopathy are complications which frequently happen during a clinical course of decompensated cirrhosis. Splanchnic and peripheral vasodilatation, increased intrarenal vasoconstriction and impaired cardiac responsive function are pathological changes causing systemic and hemodynamic derangement. Extreme renal vasoconstriction leads to severe reduction of renal blood flow and glomerular filtration rate, which finally evolves into the clinical feature of HRS. Clinical manifestations of type 1 and type 2 HRS come to medical attention differently. Patients with type 1 HRS present as acute kidney injury whereas those with type 2 HRS will have refractory ascites as the leading problem. Prompt diagnosis of type 1 HRS can halt the progression of HRS to acute tubular necrosis if the combined treatment of albumin infusion and vasoconstrictors is started timely. HRS reversal was seen in 34%-60% of patients, followed with decreasing mortality. Baseline serum levels of creatinine less than 5 mg/dL, bilirubin less than 10 mg/dL, and increased mean arterial pressure of over 5 mmHg by day 3 of the combined treatment of vasoconstrictor and albumin are the predictors of good response. Type 1 HRS can be prevented in some conditions such as albumin infusion in SBP, prophylactic antibiotics for upper gastrointestinal hemorrhage, albumin replacement after large volume paracentesis in cirrhotic patients with massive ascites. The benefit of albumin infusion in infection with primary source other than SBP requires more studies.

摘要

自发性细菌性腹膜炎(SBP)、难治性腹水、肝肾综合征(HRS)、低钠血症和肝性脑病是失代偿期肝硬化临床过程中经常发生的并发症。内脏和外周血管扩张、肾内血管收缩增加以及心脏反应功能受损是导致全身和血流动力学紊乱的病理变化。极端的肾血管收缩导致肾血流量和肾小球滤过率严重降低,最终演变为HRS的临床特征。1型和2型HRS的临床表现引起医疗关注的方式不同。1型HRS患者表现为急性肾损伤,而2型HRS患者则以难治性腹水为主要问题。如果及时开始白蛋白输注和血管收缩剂联合治疗,1型HRS的及时诊断可阻止HRS进展为急性肾小管坏死。34% - 60%的患者出现HRS逆转,随后死亡率降低。联合使用血管收缩剂和白蛋白治疗第3天,基线血清肌酐水平低于5 mg/dL、胆红素低于10 mg/dL以及平均动脉压升高超过5 mmHg是反应良好的预测指标。在某些情况下,如SBP时输注白蛋白、上消化道出血时预防性使用抗生素、大量腹水的肝硬化患者大量放腹水后补充白蛋白,可预防1型HRS。白蛋白输注对非SBP原发性感染的益处需要更多研究。

相似文献

1
Current position of vasoconstrictor and albumin infusion for type 1 hepatorenal syndrome.
World J Gastrointest Pharmacol Ther. 2015 Aug 6;6(3):28-31. doi: 10.4292/wjgpt.v6.i3.28.
2
[Hepatorenal syndrome].
Srp Arh Celok Lek. 2007 Jan-Feb;135(1-2):98-104.
3
Management of ascites and hepatorenal syndrome.
Hepatol Int. 2018 Feb;12(Suppl 1):122-134. doi: 10.1007/s12072-017-9815-0. Epub 2017 Aug 23.
4
Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1.
Gastroenterology. 2016 Jun;150(7):1579-1589.e2. doi: 10.1053/j.gastro.2016.02.026. Epub 2016 Feb 16.
7
Optimal management of hepatorenal syndrome in patients with cirrhosis.
Hepat Med. 2010 Jun 21;2:87-98. doi: 10.2147/hmer.s6918.
8
Hepatorenal syndrome.
South Med J. 2010 Jul;103(7):654-61. doi: 10.1097/SMJ.0b013e3181e07751.

引用本文的文献

1
Acute Kidney Injury in Patients with Chronic Liver Disease: A Review.
Indian J Nephrol. 2025 Jan-Feb;35(1):21-28. doi: 10.25259/ijn_333_23. Epub 2024 Jun 24.
2
Liver cirrhosis: current status and treatment options using western or traditional Chinese medicine.
Front Pharmacol. 2024 Jul 16;15:1381476. doi: 10.3389/fphar.2024.1381476. eCollection 2024.

本文引用的文献

2
Outcomes of patients with cirrhosis and hepatorenal syndrome type 1 treated with liver transplantation.
Liver Transpl. 2015 Mar;21(3):300-7. doi: 10.1002/lt.24049. Epub 2015 Feb 10.
3
Terlipressin versus norepinephrine in the treatment of hepatorenal syndrome: a systematic review and meta-analysis.
PLoS One. 2014 Sep 9;9(9):e107466. doi: 10.1371/journal.pone.0107466. eCollection 2014.
4
Review article: advances in the management of patients with cirrhosis and portal hypertension-related renal dysfunction.
Aliment Pharmacol Ther. 2014 Apr;39(7):699-711. doi: 10.1111/apt.12653. Epub 2014 Feb 13.
5
Terlipressin and albumin for type-1 hepatorenal syndrome associated with sepsis.
J Hepatol. 2014 May;60(5):955-61. doi: 10.1016/j.jhep.2013.12.032. Epub 2014 Jan 18.
6
Hepatorenal syndrome type 1 and bacterial infection: a catastrophic association in patients with cirrhosis.
Hepatology. 2014 Apr;59(4):1239-41. doi: 10.1002/hep.27015. Epub 2014 Feb 28.
8
Terlipressin for hepatorenal syndrome.
Cochrane Database Syst Rev. 2012 Sep 12(9):CD005162. doi: 10.1002/14651858.CD005162.pub3.
9
Albumin for bacterial infections other than spontaneous bacterial peritonitis in cirrhosis. A randomized, controlled study.
J Hepatol. 2012 Oct;57(4):759-65. doi: 10.1016/j.jhep.2012.06.013. Epub 2012 Jun 23.
10
Recent advances in our understanding of hepatorenal syndrome.
Nat Rev Gastroenterol Hepatol. 2012 May 22;9(7):382-91. doi: 10.1038/nrgastro.2012.96.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验